Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 4:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 858 matching trials from the live ClinicalTrials.gov search.
Conditions
Breast Cancer, Solid Tumors, Adult
Interventions
STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole, Anastrozole, Exemestane, Tamoxifen, Abemaciclib, Imlunestrant, Metformin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
28
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more
Conditions
HER2-positive Breast Cancer
Interventions
RO7771950, Tucatinib, Trastuzumab, Capecitabine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
17
States / cities
Huntsville, Alabama • Gilbert, Arizona • Clovis, California + 13 more
Conditions
HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
HER-2/neu peptide vaccine, sargramostim, rintatolimod
Biological · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Breast Cancer
Interventions
Paclitaxel, microarray analysis, biopsy, neoadjuvant therapy
Drug · Genetic · Procedure
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Breast Cancer
Interventions
Gedatolisib, Palbociclib, Letrozole, Fulvestrant
Drug
Lead sponsor
Celcuity Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
41
States / cities
Birmingham, Alabama • Corona, California • Fountain Valley, California + 17 more
Conditions
Breast Cancer
Interventions
lapatinib ditosylate, letrozole, placebo
Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
4
States / cities
Boston, Massachusetts • Nashville, Tennessee
Conditions
Locally Advanced (Inoperable) or Metastatic Breast Cancer
Interventions
Capivasertib, Fulvestrant, Palbociclib, Ribociclib, Abemaciclib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
893 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
40
States / cities
Tucson, Arizona • Fountain Valley, California • Glendale, California + 35 more
Conditions
Stage IV (Metastatic) Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer, HER2-negative Breast Cancer, Invasive Breast Cancer
Interventions
NERATINIB, FULVESTRANT
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Nashville, Tennessee
Conditions
Breast Cancer
Interventions
Ribociclib, Postoperative Radiation Therapy
Drug · Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
3
States / cities
Ann Arbor, Michigan • Wyoming, Michigan • Cleveland, Ohio
Conditions
Breast Cancer With Low to Intermediate HER2 Expression
Interventions
NeuVax™ vaccine, Leukine® (sargramostim, GM-CSF) and water for injection
Biological
Lead sponsor
Galena Biopharma, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
81
States / cities
Bessemer, Alabama • Mobile, Alabama • Peoria, Arizona + 65 more
Conditions
Advanced, Metastatic Breast Cancer
Interventions
Ribociclib, Letrozole, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Female only
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
73
States / cities
Chandler, Arizona • Sedona, Arizona • Fayetteville, Arkansas + 62 more
Terminated Phase 1Phase 2 Interventional Results available

Fasting on Newly Diagnosed Breast Cancer

NCT02379585
Conditions
HER2-positive Breast Cancer
Interventions
Doxorubicin, cyclophosphamide, paclitaxel, docetaxel, Trastuzumab, Pertuzumab
Drug
Lead sponsor
Western Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Goodyear, Arizona
Conditions
HER2 Positive Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Triple Negative Breast Neoplasms, HER2 Mutations Breast Neoplasms
Interventions
ladiratuzumab vedotin, Trastuzumab
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
38
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 30 more
Conditions
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer
Interventions
Pembrolizumab, Olaparib, Radiation
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Active, not recruiting Phase 2 Interventional Results available

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

NCT04448886
Conditions
Invasive Breast Cancer, Metastatic Breast Cancer, HR-Positive Breast Cancer, HER2-negative Breast Cancer
Interventions
Pembrolizumab, Sacituzumab Govitecan
Drug
Lead sponsor
Ana C Garrido-Castro, MD
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 5 more
Conditions
HER2-positive Breast Cancer
Interventions
Atezolizumab, Paclitaxel, Trastuzumab, Pertuzumab
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Interventions
AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor + AI, mTOR inhibitor + SERD, mTOR inhibitor + Selective estrogen receptor modulator, PI3K inhibitor + SERD, PI3K inhibitor + AI, Chemotherapy, Oral SERD, PARPi, AKT inhibitor, Step 3 Arm 2
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Miami, Florida
Conditions
HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
HER-2/neu peptide vaccine
Biological
Lead sponsor
University of Washington
Other
Eligibility
19 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Breast Cancer
Interventions
Trastuzumab
Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
8
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Conditions
Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
Interventions
Palazestrant, Fulvestrant, Anastrozole, Letrozole, Exemestane
Drug
Lead sponsor
Olema Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
47
States / cities
Tucson, Arizona • Fountain Valley, California • Glendale, California + 39 more
Conditions
Breast Cancer
Interventions
Vepdegestrant, Palbociclib
Drug
Lead sponsor
Arvinas Estrogen Receptor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
16
States / cities
Palo Alto, California • San Francisco, California • Santa Monica, California + 12 more
Conditions
Metastatic Breast Cancer, HER2-positive Breast Cancer
Interventions
BDC-1001, Pertuzumab
Drug
Lead sponsor
Bolt Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Irvine, California • New York, New York • Arlington, Virginia
Conditions
Breast Neoplasms, Lung Neoplasms
Interventions
Dexamethasone oral
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Breast Cancer
Interventions
GDC-4198, Giredestrant, Abemaciclib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
33
States / cities
Huntsville, Alabama • Tucson, Arizona • Duarte, California + 29 more